Bayer Pharma Aktiengesellschaft

Siemens Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Aktiengesellschaft

Hubertus Pietsch

Gregor Jost

Thomas Frenzel

Markus Berger

Christoph-Stephan Hilger

Olaf Panknin

Jessica Lohrke

Johannes Platzek

Detlev Suelzle

Thomas Flohr

Karl Stierstorfer

Bernhard Schmidt

Hanns-Joachim Weinmann

Detlev Sülzle

Michael Grasruck

Thomas Brumby

Sven Wittrock

Simon Anthony Herbert

Bernhard Krauβ

Martin Rohrer

Gesine Knobloch

Claus-Peter Reisinger

Harald Kramer

Ivo Matteo Baltruschat

Rüdiger Lawaczeck

Matthias Lenga

Claudia Green

Felix Karl Kreis

Gunnar SCHÜTZ

Christian Lienerth

Thomas Fenzel

An aqueous pharmaceutical composition including compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclododecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

Gadolinium chelate compounds for use in magnetic resonance imaging

The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents.

High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging

A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[({2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl}amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

A method for the automatic determination of a contrast agent protocol for a contrast agent-enhanced medical imaging method is described. The method includes an overview recording of a region of interest of an object under examination. In addition, an image recording protocol including a plurality of recording parameters is defined on the basis of the overview recording. Furthermore, recording time points are determined for a plurality of z-positions of the region of interest on the basis of the image recording protocol. In addition, the structures acquired with the overview recording are assigned to the recording time points determined. Finally, a contrast agent protocol including the temporal course of a contrast agent injection curve is defined as a function of the acquired structures and the assigned recording time points. A contrast agent protocol determination device is also described, as well as an imaging medicinal device.

Determination of a time-dependent contrast agent injection curve as a function of CT scan parameters

The present invention relates to a new class of high relaxivity extracellular gadolinium chelate complexes, to methods of preparing said compounds, and to the use of said compounds as MRI contrast agents. 

A method of predetermining the time profile of a contrast agent concentration at a vessel position is provided in the context of contrast agent-enhanced MRI of a region of interest only during the initial flooding-in phase of the contrast agent into the vessel situated in the region of interest. The method includes establishing a broadening of a contrast agent bolus profile according to the equation &#x394;W=W&#x2212;Wwherein Wis a first width of the contrast agent bolus profile at a first vessel position and Wis a second width of a contrast agent concentration profile at a second vessel position within the region of interest. The broadening is established by determining at least one flow parameter which is dependent on at least one blood flow property of the patient at a third vessel position thereof and which correlates with the broadening of the contrast agent profile.

Method for optimizing the predetermination of the time profile of a contrast agent concentration in diagnostic imaging using a magnetic resonance system

A compound having the formula of tetragadolinium [4,10-bis(carboxylatomethyl)-7-{-3,6,12,15-tetraoxo-16-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]-9,9-bis({[{2-[4,7,10-tris(carboxylatomethyl)-1,4,7,10-tetraazacyclododecan-1-yl]propanoyl} amino)acetyl]amino}methyl)-4,7,11,14-tetraazaheptadecan-2-yl}-1,4,7,10-tetraazacyclo dodecan-1-yl]acetate wherein the stereochemistry at the chiral carbon of the four alanine substituents is selected from the group consisting of RRRR, SSSS, RSSS, RRSS, and RRRS stereoisomers, and racemic and diastereomeric mixtures of any thereof, or a tautomer, a hydrate, a solvate, or a salt thereof, or a mixture of same is described. The compounds may be used as an MRI contrast imaging agent.

A mammography CT system is disclosed which includes an X-ray generator; and a first radiator-detector system. A contrast medium, including an opacifying element including an absorption peak in a first energy range, is useable for tomographic imaging of a female breast of a patient. After filtering, the X-rays with a prespecified tube voltage that form at an anode, are configured to emit an X-ray spectrum having a second energy range, wherein the radiator-detector system is configured to acquire a plurality of circumferential projections around the breast. The first energy range is a part of the second energy range and the second energy range includes an upper limit of less than 70 keV and a lower limit of greater than 20 keV. A corresponding method for generating tomographic mammography CT images is also disclosed.

Combination of contrast medium and mammography CT system with a prespecified energy range and method for generating tomographic mammography CT images by this combination

A method is disclosed for selecting two contrast agents to be used in a dual energy CT examination of a patient. In at least one embodiment, the method includes determining the gradient of a connecting line between a first material or a first tissue type and a second material or second tissue type in an HU value diagram of the energy-specific HU values, selecting a first contrast agent with an enhancement gradient which is significantly greater than the determined base gradient, and selecting a second contrast agent, the enhancement of which lies in the significance region of the determined base gradient. A contrast agent combination selected in the fashion is also disclosed in at least one embodiment, as well as the generation of CT images using a contrast agent combination selected in the fashion and using different energy spectra.

Selection method for two contrast media for use in a dual-energy CT examination, contrast media combination and generation of CT images using a contrast media combination and different energy spectra

An x-ray system is disclosed including a selector for finding an optimum combination between the contrast medium and the energy spectrum of an x-radiation for a scan to optimize the noise-to-contrast ratio. A method for creating X-ray images is also provided. The x-ray images are created with the aid of contrast media by taking into account an optimal combination between the contrast medium and the energy spectrum of an X-radiation used for a scan. A method for the use of a lanthanide-containing complex to produce a contrast medium for optimizing the combination between the contrast medium and the radiation to obtain a maximum contrast-to-noise ratio in an X-ray image is also provided.

X-ray system for the creation of diagnostic X-ray images using contrast media

Growing community of inventors

Kleinmachnow, Germany

Hubertus Pietsch